The U.S. Food and Drug Administration has approved erenumab (Aimovig™, Amgen and Novartis), a first-in-class calcitonin gene-related peptide (CGRP) antagonist, for the prevention of migraine in adults.

Erenumab consistently demonstrated an ability to reduce monthly migraine days in patients with episodic and chronic migraine in 3 major clinical trials, ARISE, STRIVE, and LIBERTY. The drug, which is indicated for once-monthly use, will be available to patients in both a 70 mg and 140 mg self-administered auto-injector within 1 week of the approval.

Read Full Article